Aprea Therapeutics, Inc.
APRE
$0.79
$0.000.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 83.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 83.33% | |||
| Cost of Revenue | 59.71% | -38.45% | |||
| Gross Profit | -60.24% | 38.58% | |||
| SG&A Expenses | 11.09% | 10.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 29.63% | -15.16% | |||
| Operating Income | -29.79% | 15.21% | |||
| Income Before Tax | -33.89% | 17.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -33.89% | 17.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.89% | 17.39% | |||
| EBIT | -29.79% | 15.21% | |||
| EBITDA | -29.85% | 15.24% | |||
| EPS Basic | 29.90% | 31.52% | |||
| Normalized Basic EPS | 29.91% | 31.53% | |||
| EPS Diluted | 29.90% | 31.52% | |||
| Normalized Diluted EPS | 29.91% | 31.53% | |||
| Average Basic Shares Outstanding | 91.02% | 20.64% | |||
| Average Diluted Shares Outstanding | 91.02% | 20.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||